ENGN · enGene Therapeutics Inc. · Financials
The latest filing states the doubt was alleviated.
“In accordance with Accounting Standards Codification ("ASC") 205-40, Going Concern, the Company has evaluated whether there are any conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date these consolidated financial statements are issued. As of the issuance date of these consolidated financial statements, the Company expects that its existing cash, cash equivalents and marketable securities as of April 30, 2026 will be sufficient to fund its operating expenses and debt obligations requirements for at least the next 12 months.”View the 10-Q filed Jun 15, 2026
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| $96.26M | $94.48M | $38.32M | $16.46M | $15.47M | |
| $40.39M | $28.69M | $23.98M | $9.6M | $3.96M | |
| $687K | $500K | $300K | $200K | $200K | |
| $136.65M | $123.17M | $62.3M | $26.06M | $19.43M | |
| -$136.65M | -$123.17M | -$62.3M | -$26.06M | -$19.43M | |
| $3.07M | $2.99M | $2.8M | $4.95M | $1.42M | |
| $9.78M | $9.43M | $10.41M | $1.12M | $129K | |
| $5.79M | $5.86M | $7.14M | -$73.84M | -$5.01M | |
| -$130.86M | -$117.3M | -$55.16M | -$99.9M | -$24.44M | |
| -$497K | $0 | -$19K | $17K | $22K | |
| -$130.36M | -$117.3M | -$55.14M | -$99.92M | -$24.46M | |
| -$130.36M | -$117.3M | -$55.14M | -$104.74M | -$29.02M | |
| -$130.5M | -$116.77M | -$54.74M | -$99.92M | -$23.3M | |
| USD/shares | $2.43 | $2.29 | $1.46 | $151.22 | $44.30 |
| USD/shares | $2.43 | $2.29 | $1.46 | $151.22 | $44.30 |
| shares | — | 51.12M | 37.78M | 692.61K | 655.15K |
| shares | — | 51.12M | 37.78M | 692.61K | 655.15K |
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Current portion of notes payable | 2026-07-31 | USD 199,000 | 10-Q filed 2026-09-08 |
| Noncurrent notes payable | 2026-07-31 | USD 25,155,000 | 10-Q filed 2026-09-08 |
| Operating lease liabilities | 2026-07-31 | USD 7,917,000 | 10-Q filed 2026-09-08 |
Related accounting measures — not additional borrowingCarrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.
| |||
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 304 similar-size Biotechnology companies (of 531 listed).